Interventions
REPAIR-MS
PROGRESSIVE MULTIPLE SCLEROSIS, BLIND
Participants took the assigned dose of CNM-Au8 once daily for at least 12 weeks. Study investigators and participants were blinded to the dose of CNM-Au8 selected by the sponsor, which could range from 7.5 mg to 60 mg CNM-Au8; the blind will be maintained until another companion cohort of the REPAIR-MS trial in non-active progressive multiple sclerosis, which is currently underway, is completed.